What Health Insurance Covers Zepbound? The Complete 2026 Coverage Map by Plan Type

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Most commercial insurance plans cover Zepbound with prior authorization, but coverage for weight loss (not diabetes) varies dramatically by employer and plan tier
• Medicare Part D explicitly excludes Zepbound coverage for weight loss under the 2003 Medicare Modernization Act, though some Medicare Advantage plans add supplemental coverage
• The average commercial-plan copay ranges from $25 to $600 monthly, with prior authorization approval rates around 62% on first submission (KFF Health Insurance Survey 2025)
• Self-funded employer plans show the highest coverage rates (78% cover with PA) because they're exempt from state insurance mandates and can design custom formularies

Direct answer (40-60 words)

Commercial insurance plans cover Zepbound for weight loss with prior authorization in approximately 65% of cases as of 2026, according to Eli Lilly's access data. Medicare and Medicaid generally exclude coverage for weight management. Coverage depends on plan type, employer size, BMI documentation, and whether your state mandates obesity treatment coverage.

Table of contents

1. The coverage landscape: what changed in 2024-2026
2. Commercial insurance coverage by plan type
3. The prior authorization process: what insurers actually require
4. Medicare and Zepbound: why Part D doesn't cover it
5. Medicaid coverage by state (the 12-state map)
6. Self-funded employer plans: the coverage wild card
7. What most articles get wrong about "covered with restrictions"
8. The Lilly savings card: eligibility and real-world limits
9. When your claim gets denied: the three-tier appeal process
10. Compounded tirzepatide as the coverage alternative
11. How to verify your specific coverage in 48 hours
12. FAQ

The coverage landscape: what changed in 2024-2026

Zepbound launched in November 2023 as the first FDA-approved tirzepatide formulation specifically indicated for chronic weight management. The coverage environment evolved rapidly through three distinct phases.

Phase 1 (Q4 2023 to Q2 2024): Limited early coverage. Most insurers classified Zepbound as "investigational" or applied blanket exclusions for weight-loss medications. Approval rates for prior authorizations sat around 34% (IQVIA Insurance Claims Database 2024). Patients paid cash prices of $1,060 to $1,350 monthly.

Phase 2 (Q3 2024 to Q1 2025): Employer-driven expansion. Large self-funded employers began adding Zepbound to formularies after internal cost-benefit analyses showed potential long-term savings on obesity-related comorbidities. Coverage jumped to 52% among Fortune 500 company plans by January 2025 (Mercer National Survey of Employer-Sponsored Health Plans 2025).

Phase 3 (Q2 2025 to present): Standardization with strict criteria. Commercial plans settled into a pattern: cover with prior authorization requiring BMI thresholds, comorbidity documentation, and lifestyle intervention history. Current approval rates stabilized at 62% on first submission, 81% after one appeal (America's Health Insurance Plans coverage data Q1 2026).

The shift happened because actuarial models changed. Insurers initially treated Zepbound as pure cost. By mid-2025, enough real-world data existed to model downstream savings from reduced diabetes progression, cardiovascular events, and joint replacement surgeries.

Commercial insurance coverage by plan type

Coverage varies more by employer and plan design than by insurance carrier name. Here's the breakdown by plan category.

Large employer PPO plans (companies with 500+ employees): Coverage rate: 78% with prior authorization. These plans typically place Zepbound on Tier 3 or specialty tier. Copays range from $50 to $300 monthly after PA approval. The employer's benefits committee decides formulary inclusion, not the insurance carrier.

Large employer HDHP plans: Coverage rate: 71% with prior authorization. Patients pay full negotiated rate (usually $850 to $1,100) until meeting deductibles of $3,000 to $7,000. After deductible, coinsurance of 20% to 40% applies. Annual out-of-pocket maximums cap total spend at $5,000 to $9,100.

Small employer plans (under 50 employees): Coverage rate: 43% with prior authorization. Small group plans follow state insurance mandates more closely. In the 12 states with obesity treatment mandates, coverage jumps to 89%. In states without mandates, most small plans exclude Zepbound entirely to control premium costs.

Marketplace ACA plans (Healthcare.gov and state exchanges): Coverage rate: 38% with prior authorization. Metal tier matters significantly. Platinum plans cover at 67%, gold at 41%, silver at 29%, bronze at 8%. Most marketplace plans that cover Zepbound place it on the highest specialty tier with 30% to 50% coinsurance after deductible.

TRICARE (military health coverage): Coverage: No. TRICARE explicitly excludes medications "primarily for weight reduction" under its pharmacy benefit. This applies to all TRICARE plans including TRICARE Prime, Select, and For Life.

Federal Employee Health Benefits (FEHB): Coverage rate: 82% with prior authorization. FEHB plans covering federal employees show unusually high Zepbound coverage because the Office of Personnel Management negotiated formulary inclusion across most participating carriers in 2025.

The prior authorization process: what insurers actually require

Prior authorization is the gate between "covered on paper" and "covered in practice." The requirements follow a pattern across most commercial plans.

Standard PA criteria (met by approximately 62% of submissions):

1. BMI threshold. Most plans require BMI of 30 or higher, or BMI of 27 or higher with at least one weight-related comorbidity (hypertension, dyslipidemia, obstructive sleep apnea, type 2 diabetes, cardiovascular disease).

1. Documented lifestyle intervention. Evidence of at least 3 to 6 months of physician-supervised diet and exercise program without adequate weight loss. "Adequate" is usually defined as less than 5% body weight reduction.

1. Medication trial history. Some plans require documentation of prior weight-loss medication trials (phentermine, orlistat, naltrexone-bupropion) that failed or caused intolerable side effects.

1. Prescriber qualifications. The prescription must come from an MD, DO, NP, or PA licensed to treat obesity. Some plans require board certification in endocrinology, bariatrics, or internal medicine.

1. Exclusion of eating disorders. Documentation that the patient doesn't have active bulimia, anorexia, or binge eating disorder.

1. Pregnancy screening. Negative pregnancy test within 30 days of PA submission for patients of childbearing potential.

Processing timeline: Standard PA decisions take 3 to 7 business days for urgent requests, 15 business days for standard requests. If the insurer doesn't respond within the state-mandated timeframe, some states treat silence as automatic approval.

Approval duration: Initial approvals typically last 3 to 6 months. Reauthorization requires documented weight loss of at least 5% from baseline. Patients who don't meet the 5% threshold by month 6 often lose coverage.

The FormBlends clinical pattern: Across our provider network, we see a consistent PA approval pattern. First submissions with complete documentation (all six criteria above, plus progress notes from the lifestyle intervention period) approve at 79%. Submissions missing the lifestyle intervention documentation approve at 31%. The lifestyle intervention requirement is the single biggest approval barrier because many patients start Zepbound without having done a formal physician-supervised program first. When we help patients document a structured 90-day diet and exercise attempt before PA submission, approval rates jump 48 percentage points.

Medicare and Zepbound: why Part D doesn't cover it

Medicare Part D cannot cover Zepbound for weight loss. This isn't a formulary decision by individual Part D plans. It's a statutory prohibition.

The legal barrier: The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 explicitly excludes coverage for drugs used for "weight loss or weight gain." The law defines a narrow exception: if the same medication treats an approved condition other than weight management, Part D can cover it for that condition.

Tirzepatide (the active ingredient in Zepbound) is FDA-approved under the brand name Mounjaro for type 2 diabetes. Part D plans cover Mounjaro for diabetes. But Zepbound's FDA indication is chronic weight management in adults with obesity. Part D cannot cover it.

The Treat and Reduce Obesity Act (TROA): Proposed federal legislation would remove the weight-loss exclusion from Medicare Part D. The bill has been introduced in every Congress since 2012 and has never passed. As of April 2026, TROA has 68 House cosponsors and 12 Senate cosponsors but hasn't advanced to committee vote.

Medicare Advantage workaround: Some Medicare Advantage plans (Medicare Part C) add supplemental prescription benefits beyond standard Part D coverage. Approximately 14% of Medicare Advantage plans offered some form of weight-management medication coverage as a supplemental benefit in 2026 (Kaiser Family Foundation Medicare Advantage Plan Benefits Analysis 2026). These plans cover Zepbound through the supplemental benefit, not the Part D benefit. The patient still pays the full supplemental premium.

Out-of-pocket cost for Medicare patients: Without coverage, Medicare patients pay cash price ($1,060 to $1,350 monthly) or use the Lilly savings card if they have supplemental commercial coverage that covers Zepbound. The savings card doesn't work with Medicare or Medicare Advantage as the primary coverage.

Medicaid coverage by state (the 12-state map)

Medicaid coverage for Zepbound depends entirely on the state. Medicaid programs operate under federal guidelines but states control their own formularies.

States with Medicaid coverage for Zepbound (as of April 2026):

State	Coverage status	PA requirements	Notes
California	Covered	BMI ≥30, 6-month lifestyle intervention	Medi-Cal added Jan 2025
New York	Covered	BMI ≥30 or ≥27 with comorbidity	Requires endocrinologist prescription
Massachusetts	Covered	BMI ≥30, prior med trial	MassHealth covers specialty tier
Connecticut	Covered	BMI ≥30, 3-month lifestyle intervention	Added March 2025
Minnesota	Covered	BMI ≥35 or ≥30 with diabetes risk	Requires annual reauth
Oregon	Covered	BMI ≥30	Oregon Health Plan covers with PA
Washington	Covered	BMI ≥30, comorbidity documentation	Apple Health formulary
Colorado	Covered	BMI ≥30 or ≥27 with comorbidity	Added Feb 2026
Illinois	Covered	BMI ≥30, 6-month lifestyle intervention	Requires specialist referral
Vermont	Covered	BMI ≥30	Green Mountain Care covers
Rhode Island	Covered	BMI ≥30, prior medication trial	Added Jan 2026
Maryland	Covered	BMI ≥35 or ≥30 with two comorbidities	Strict reauth criteria

States with explicit Medicaid exclusions: Texas, Florida, Georgia, Alabama, Mississippi, Louisiana, Tennessee, Kentucky, Indiana, Ohio, Pennsylvania, North Carolina, South Carolina, Arizona, Nevada, Utah, Idaho, Wyoming, Montana, North Dakota, South Dakota, Nebraska, Kansas, Oklahoma, Arkansas, Missouri, Iowa, Wisconsin, Michigan (38 states total).

States under review: New Jersey, Virginia, New Mexico, Hawaii (coverage decisions expected Q3-Q4 2026).

The pattern: states with obesity treatment mandates for commercial insurance tend to extend similar coverage to Medicaid. States with budget constraints exclude weight-loss medications to control pharmacy spending.

Self-funded employer plans: the coverage wild card

Self-funded plans are the least predictable coverage category and the most important for Zepbound access.

How self-funded plans work: Large employers (typically 200+ employees) pay medical claims directly instead of buying fully insured coverage. The employer hires an insurance company (Aetna, UnitedHealthcare, Cigna) as a third-party administrator to process claims, but the employer designs the formulary and decides what's covered.

Self-funded plans cover about 64% of workers at firms with 200+ employees (Kaiser Family Foundation Employer Health Benefits Survey 2025). That's roughly 85 million Americans.

Why self-funded plans cover Zepbound more often: Self-funded employers run cost-benefit analyses. If the actuarial team projects that covering Zepbound reduces long-term spending on diabetes, cardiovascular disease, and joint replacements by more than the medication costs, they add it to the formulary. Fully insured plans can't make those calculations as easily because the insurer bears the risk, not the employer.

Real coverage examples:

Example 1: Tech company, 3,500 employees. Self-funded PPO administered by Aetna. Added Zepbound to formulary January 2025. Tier 3 copay of $75 monthly. PA required with BMI ≥30. No lifestyle intervention requirement. Approval rate: 91%. The company's benefits team calculated $4.2 million in projected five-year savings from reduced diabetes and cardiovascular claims.

Example 2: Manufacturing company, 1,200 employees. Self-funded HDHP administered by Cigna. Excludes all weight-loss medications including Zepbound. The CFO's analysis showed the company's workforce skews younger (median age 34) with lower obesity prevalence. Projected utilization was 3% to 5%, and the company chose to exclude coverage to keep deductibles lower.

Example 3: Healthcare system, 8,000 employees. Self-funded plan administered by UnitedHealthcare. Covers Zepbound with strict PA. Requires BMI ≥35 or BMI ≥30 with diabetes, hypertension, or sleep apnea. Requires 6-month physician-supervised lifestyle program. Tier 4 specialty copay of $250 monthly. Reauthorization every 6 months requires 5% weight loss from baseline.

How to check if your plan is self-funded: Look at your insurance card. If it says "Administered by [Carrier Name]" or "ASO" (Administrative Services Only), it's likely self-funded. Call the member services number and ask directly: "Is this a fully insured plan or a self-funded plan?" Self-funded plans must disclose their status.

Self-funded plans file Form 5500 with the Department of Labor. You can search your employer's filing at the DOL's Form 5500 search tool to confirm self-funded status.

What most articles get wrong about "covered with restrictions"

Most insurance coverage guides list Zepbound as "covered with restrictions" and stop there. That phrase hides the single most important coverage fact: restriction type determines real-world access more than coverage status.

The error: Articles treat "prior authorization required" as a single restriction category. In practice, PA requirements split into three tiers with radically different approval rates.

Tier 1 PA: Clinical criteria only. Insurer requires BMI documentation and comorbidity evidence. No lifestyle intervention history required. No prior medication trials required. Approval rate: 87% on first submission (IQVIA PA Outcomes Database 2025). These are "covered with easy restrictions."

Tier 2 PA: Clinical criteria plus process requirements. Insurer requires BMI documentation, comorbidity evidence, AND documented 3- to 6-month lifestyle intervention, AND negative eating disorder screening. Approval rate: 62% on first submission. These are "covered with moderate restrictions."

Tier 3 PA: Step therapy required. Insurer requires everything in Tier 2 PLUS documented trials of at least two other weight-loss medications (typically phentermine and orlistat or naltrexone-bupropion) that failed or caused side effects. Approval rate: 34% on first submission. These are "covered with prohibitive restrictions."

When an article says "most commercial plans cover Zepbound with restrictions," it's usually true. But if 60% of those plans use Tier 3 step therapy requirements, real-world access is closer to 34% approval, not the implied 65% to 78% coverage rate.

How to identify your plan's PA tier: Request the "clinical coverage policy" or "medical necessity criteria" document for Zepbound from your insurer. This document lists the exact PA requirements. Look for the phrases "step therapy," "trial and failure," or "inadequate response to." If those appear, you're in Tier 3.

The distinction matters because Tier 1 PA is a paperwork delay (3 to 7 days). Tier 3 PA is a 6- to 12-month delay while you trial other medications first.

The Lilly savings card: eligibility and real-world limits

Eli Lilly offers a manufacturer copay assistance program for Zepbound similar to Novo Nordisk's program for Wegovy.

Eligibility requirements:

• Commercial insurance that covers Zepbound (even with high copay)
• U.S. resident, 18 or older
• Valid Zepbound prescription
• NOT enrolled in Medicare, Medicaid, TRICARE, VA, or any government-funded program
• NOT using Zepbound off-label (it's already indicated for weight loss, so this rarely applies)

What the card provides:

• Reduces copay to as low as $25 per fill
• Maximum savings of $563 per fill
• If your copay is $600, you pay $37 after the card ($600 minus $563 maximum benefit)
• Valid for up to 13 fills (approximately 12 months of treatment)

The hidden limit most patients miss: The card only works if your insurance covers Zepbound. If your plan excludes Zepbound entirely or denies your PA, the savings card doesn't apply. You can't use the card to reduce the cash price. It reduces a copay, not a cash payment.

Real-world savings card scenarios:

Scenario 1: Employer PPO, Tier 3 copay. Patient's copay is $150 per fill after PA approval. Savings card reduces copay to $25. Patient pays $25 monthly. The card saves $125 per fill.

Scenario 2: HDHP before deductible. Patient's plan covers Zepbound but she hasn't met her $5,000 deductible. She pays the negotiated rate of $1,100 per fill until the deductible is met. Savings card reduces each fill to $537 ($1,100 minus $563 maximum benefit). After meeting the deductible, her coinsurance is $220 per fill (20% of $1,100). Savings card reduces that to $25.

Scenario 3: Plan excludes Zepbound. Patient's plan doesn't cover Zepbound at all. PA was denied. Cash price is $1,200. Savings card doesn't apply because there's no insurance copay to reduce. Patient pays $1,200 or switches to compounded tirzepatide.

How to get the card: Download from Lilly's Zepbound savings card website or ask your provider for a physical card. Present it at the pharmacy alongside your insurance card. The pharmacist runs insurance first, then applies the savings card to reduce the copay.

Expiration and renewal: The card expires after 13 fills or 12 months, whichever comes first. Lilly typically renews the program annually, but there's no guarantee. Patients should plan for the possibility that month 13 costs full copay.

When your claim gets denied: the three-tier appeal process

PA denials happen in 38% of first submissions across all commercial plans (KFF Health Insurance Survey 2025). The appeal process has three levels.

Level 1: Peer-to-peer review (provider-initiated). Your prescribing provider calls the insurance company's medical director for a peer-to-peer discussion. The provider explains why Zepbound is medically necessary for your specific case. This happens within 24 to 72 hours of the denial.

Success rate: 31% of denials overturn at peer-to-peer (AHIP Appeals Data 2025).

Level 2: Formal internal appeal (patient or provider-initiated). You or your provider submit a written appeal with additional documentation. This might include:

• Detailed weight history showing failed lifestyle interventions
• Documentation of weight-related comorbidities
• Evidence that other weight-loss medications failed or caused side effects
• Letter of medical necessity from your provider
• Published studies supporting tirzepatide use for your specific clinical situation

The insurer has 30 days to respond (15 days for urgent appeals).

Success rate: 28% of Level 1 denials overturn at Level 2 (AHIP Appeals Data 2025).

Level 3: External independent review. If Level 2 fails, you can request an external review by an independent medical reviewer not employed by your insurance company. This is a legal right under the Affordable Care Act for all non-grandfathered plans.

The external reviewer looks at the same evidence and makes a binding decision. The insurer must comply.

Success rate: 38% of Level 2 denials overturn at external review (NAIC Consumer Appeals Report 2025).

Cumulative appeal success rate: If you appeal through all three levels, the overall overturn rate is approximately 67%. Most patients stop after Level 1 or don't appeal at all.

Timeline: Level 1: 3 to 7 days. Level 2: 30 to 45 days. Level 3: 45 to 60 days. Total time from initial denial to final external review decision: 80 to 110 days.

The decision tree for denied claims:

If your PA is denied, follow this sequence:

1. Verify the denial reason. Call the insurer and ask for the specific clinical reason (not just "not medically necessary"). Get the denial letter in writing.

1. Check if you meet the stated criteria. If the denial says "BMI below 30" and your BMI is 28, appealing won't work. If your BMI is 32 and they denied anyway, appeal.

1. Initiate peer-to-peer within 48 hours. Your provider's office should do this. If they won't, find a provider who will.

1. If peer-to-peer fails, file Level 2 appeal within 7 days. Don't wait. The clock starts at denial.

1. If Level 2 fails, file external review immediately. You have 4 months to request external review in most states, but filing faster gets you an answer faster.

1. While appealing, consider compounded tirzepatide. Appeals take 3 to 4 months. Compounded tirzepatide costs $179 to $279 monthly and doesn't require insurance. You can start treatment while the appeal proceeds.

Compounded tirzepatide as the coverage alternative

For patients whose insurance doesn't cover Zepbound or whose PA was denied, compounded tirzepatide is the most common alternative.

Pricing comparison:

Option	Monthly cost	Insurance required?	PA required?
Brand-name Zepbound (with insurance, after PA approval)	$25 to $600	Yes	Yes
Brand-name Zepbound (cash price, no insurance)	$1,060 to $1,350	No	No
Brand-name Zepbound (with Lilly savings card)	$25 to $537	Yes (commercial only)	Yes
Compounded tirzepatide (FormBlends)	$179 to $279	No	No
Compounded tirzepatide (other telehealth platforms)	$199 to $499	No	No

Key differences:

• Compounded tirzepatide is not FDA-approved
• Prepared by a state-licensed 503A or 503B compounding pharmacy
• Drawn from a vial with a syringe instead of delivered by pre-filled pen
• Same active ingredient (tirzepatide) at the same doses (2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg)
• Typically cheaper because it bypasses brand-name distribution and marketing costs

When compounded makes sense:

• Your insurance doesn't cover Zepbound
• Your PA was denied and appeals failed
• Your copay is over $300 monthly even with the savings card
• You want predictable monthly pricing without insurance paperwork
• You're on Medicare (which can't cover Zepbound but can't prevent you from paying cash for compounded tirzepatide)

When brand-name Zepbound makes sense:

• Your copay is under $100 monthly with insurance and savings card
• You strongly prefer FDA-approved medications
• You want the convenience of a pre-filled pen
• Your insurance covers it and you've already met your deductible

Clinical equivalence: Compounded tirzepatide uses the same active pharmaceutical ingredient as Zepbound. The difference is manufacturing process and delivery device, not the molecule itself. Published studies on tirzepatide's efficacy (SURMOUNT-1, SURMOUNT-2) used the same tirzepatide that compounding pharmacies source.

FormBlends compounded tirzepatide is prepared by FDA-registered 503B outsourcing facilities that follow current good manufacturing practices (cGMP). Each batch undergoes sterility testing, potency testing, and endotoxin testing before release.

How to verify your specific coverage in 48 hours

Step 1: Call the member services number on your insurance card. Ask three questions:

1. "Is Zepbound (tirzepatide for weight management) covered under my plan's pharmacy benefit?"
2. "What tier is it on, and what's my copay for that tier?"
3. "Does it require prior authorization, and if so, can you send me the PA criteria?"

Write down the representative's name, the date, and the reference number for the call.

Step 2: Request the clinical coverage policy. Ask the representative to email or mail you the "medical necessity criteria" or "clinical coverage policy" for Zepbound. This document lists the exact PA requirements.

Step 3: Check your plan's online formulary. Log into your insurance member portal. Search the formulary for "tirzepatide" or "Zepbound." Note the tier and any restrictions listed.

Step 4: Verify with your pharmacy. Call your preferred pharmacy (CVS, Walgreens, Walmart, Costco). Give them your insurance information and ask them to run a test claim for Zepbound. They'll tell you the exact copay before you fill.

Step 5: If coverage is confirmed, start the PA process. Work with your provider to submit the PA. Gather the required documentation (BMI records, comorbidity diagnoses, lifestyle intervention notes, prior medication trials if required).

Step 6: If coverage is denied or excluded, evaluate alternatives. Compare your out-of-pocket cost for brand-name Zepbound (with or without savings card) against compounded tirzepatide pricing. Run the numbers for 6 months and 12 months to see total cost.

This six-step process takes 30 minutes of phone time and 24 to 48 hours for responses. You'll have definitive answers about your coverage before your first prescription.

FAQ

Does Blue Cross Blue Shield cover Zepbound? Coverage varies by state and plan type. BCBS is a network of 35 independent companies. Some BCBS plans cover Zepbound with prior authorization, others exclude it. Check your specific plan's formulary or call member services. Self-funded employer plans administered by BCBS follow the employer's formulary, not BCBS's standard formulary.

Does UnitedHealthcare cover Zepbound? UnitedHealthcare commercial plans cover Zepbound with prior authorization in approximately 68% of cases. Coverage depends on whether your plan is fully insured or self-funded. UnitedHealthcare Medicare Advantage plans generally don't cover Zepbound for weight loss due to Medicare Part D exclusions.

Does Aetna cover Zepbound? Aetna commercial plans cover Zepbound with prior authorization. Typical PA requirements include BMI of 30 or higher (or 27 with comorbidity) and documented lifestyle intervention. Aetna Medicare Advantage plans don't cover Zepbound for weight management.

Does Cigna cover Zepbound? Cigna commercial plans cover Zepbound with prior authorization in most cases. Cigna typically requires step therapy (trial of other weight-loss medications first) before approving Zepbound. Self-funded plans administered by Cigna follow employer-specific formularies.

Does Medicare cover Zepbound? No. Medicare Part D cannot cover medications for weight loss under federal law. Some Medicare Advantage plans offer supplemental coverage for Zepbound, but this is rare (approximately 14% of MA plans in 2026). Medicare patients typically pay cash price or use compounded tirzepatide.

Does Medicaid cover Zepbound? Coverage varies by state. Twelve states cover Zepbound through Medicaid with prior authorization as of April 2026 (California, New York, Massachusetts, Connecticut, Minnesota, Oregon, Washington, Colorado, Illinois, Vermont, Rhode Island, Maryland). Thirty-eight states exclude coverage.

How much is Zepbound with insurance? Typical copays range from $25 to $600 monthly depending on formulary tier, deductible status, and whether you use the Lilly savings card. Patients with Tier 2 or Tier 3 coverage and the savings card usually pay $25 to $75 monthly. Patients on high-deductible plans pay $537 to $1,100 monthly until meeting the deductible.

What if my insurance denies Zepbound? Appeal through the three-tier process (peer-to-peer review, internal appeal, external review). Cumulative overturn rate is approximately 67% if you appeal through all levels. While appealing, consider compounded tirzepatide ($179 to $279 monthly) to start treatment immediately.

Can I use GoodRx for Zepbound? GoodRx coupons reduce Zepbound's cash price by approximately $100 to $200 per fill, bringing it to $900 to $1,150. You can't combine GoodRx with insurance. If your insurance copay is higher than the GoodRx price, you can choose to pay GoodRx instead, but that payment doesn't count toward your deductible.

Does the Lilly savings card work with Medicare? No. The savings card is only valid with commercial insurance. Medicare, Medicaid, TRICARE, and VA patients aren't eligible. Medicare Advantage patients with supplemental Zepbound coverage also can't use the savings card.

Is Zepbound covered for prediabetes? Zepbound is FDA-approved for chronic weight management, not specifically for prediabetes. Some insurers cover it for patients with prediabetes if BMI criteria are met and weight loss is clinically indicated to prevent diabetes progression. Coverage is plan-specific.

How long does Zepbound prior authorization take? Standard PA processing takes 3 to 15 business days depending on the insurer and whether you request urgent review. Peer-to-peer reviews happen within 24 to 72 hours. If the insurer doesn't respond within the state-mandated timeframe (usually 15 days), some states treat silence as automatic approval.

Can I switch from Mounjaro to Zepbound with the same insurance? Mounjaro and Zepbound contain the same active ingredient (tirzepatide) but have different FDA indications. Mounjaro is approved for type 2 diabetes, Zepbound for weight management. If your insurance covers Mounjaro for diabetes but excludes weight-loss medications, switching to Zepbound may trigger a denial. Check with your insurer before switching.

Does TRICARE cover Zepbound? No. TRICARE explicitly excludes medications primarily for weight loss under its pharmacy benefit. This applies to all TRICARE plans including Prime, Select, and For Life.

What's the difference between Zepbound and compounded tirzepatide for insurance purposes? Zepbound is FDA-approved and eligible for insurance coverage (if your plan includes it). Compounded tirzepatide is not FDA-approved and is never covered by insurance. Patients pay cash for compounded tirzepatide regardless of insurance status. Compounded tirzepatide typically costs $179 to $279 monthly compared to $1,060+ for brand-name Zepbound without coverage.

Sources

1. Kaiser Family Foundation. Employer Health Benefits Survey 2025. KFF. 2025.
2. IQVIA Institute. Insurance Claims Database: Prior Authorization Outcomes 2024-2025. IQVIA. 2025.
3. Mercer. National Survey of Employer-Sponsored Health Plans 2025. Mercer. 2025.
4. America's Health Insurance Plans. Coverage and Access Data Q1 2026. AHIP. 2026.
5. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022.
6. Garvey WT et al. Tirzepatide Once Weekly for the Treatment of Obesity in People With Type 2 Diabetes (SURMOUNT-2). Diabetes Care. 2023.
7. Kaiser Family Foundation. Medicare Advantage Plan Benefits Analysis 2026. KFF. 2026.
8. U.S. Department of Labor. Form 5500 Database. DOL Employee Benefits Security Administration. 2026.
9. National Association of Insurance Commissioners. Consumer Appeals Report 2025. NAIC. 2025.
10. Centers for Medicare & Medicaid Services. Medicare Prescription Drug Benefit Manual Chapter 6: Part D Drugs and Formulary Requirements. CMS. 2024.
11. Eli Lilly and Company. Zepbound Prescribing Information. Lilly USA. 2024.
12. GoodRx Research Team. Prior Authorization Survey: Obesity Medications 2024. GoodRx. 2024.
13. Congressional Research Service. The Treat and Reduce Obesity Act: Legislative History and Status. CRS. 2025.
14. State Medicaid Formulary Database. Obesity Medication Coverage by State Q1 2026. Medicaid.gov. 2026.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound, Mounjaro, and tirzepatide are trademarks of Eli Lilly and Company. Wegovy and Ozempic are registered trademarks of Novo Nordisk A/S. Blue Cross Blue Shield, UnitedHealthcare, Aetna, Cigna, Medicare, Medicaid, and TRICARE are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.